We scan new podcasts and send you the top 5 insights daily.
Manage the complexity of end-to-end continuous processes by creating automated feedback loops. Integrating real-time analytics, like an online HPLC, with mechanistic models allows for the dynamic, on-the-fly adjustment of downstream unit operations based on live upstream performance, optimizing the entire system.
Breakthroughs in bioprocessing occur at the intersection of molecular biology and process engineering. The most effective approach is an iterative cycle: engineer a strain for specific process needs, test it in a real bioreactor (not just a flask), and use that performance data to inform the next round of strain improvement.
By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.
The most significant breakthroughs will no longer come from traditional wet lab experiments alone. Instead, progress will be driven by the smarter application of AI and simulations, with future bioreactors being as much digital as they are physical.
The future of bioprocess development involves using AI on high-throughput data for predictive modeling. This, combined with in silico simulations (digital twins), will allow scientists to understand underlying biological mechanisms, not just identify optimal conditions, dramatically accelerating optimization.
The standard practice is to optimize for productivity (titer) first, then correct for quality (glycosylation) later. This is reactive and inefficient. Successful teams integrate glycan analysis into their very first screening experiments, making informed, real-time trade-offs between productivity and quality attributes.
The primary value of AI in bioprocessing is not just automating tasks, but analyzing process data to predict outcomes. This requires a fundamental shift in capital equipment design, focusing on integrating more sensors and methods to collect far more granular data than is standard today.
AI models mirror a bioreactor in real time, creating a "digital twin." This allows operators to test process changes and potential failure modes virtually, without touching the actual, expensive physical system, much like having a virtual engineer working alongside them.
Instead of running hundreds of brute-force experiments, machine learning models analyze historical data to predict which parameter combinations will succeed. This allows teams to focus on a few dozen targeted experiments to achieve the same process confidence, compressing months of work into weeks.
The next evolution of biomanufacturing isn't just automation, but a fully interconnected facility where AI analyzes real-time sensor data from every operation. This allows for autonomous, predictive adjustments to maintain yield and quality, creating a self-correcting ecosystem that prevents deviations before they impact production.
Two critical mistakes derail glycoengineering efforts. First, delaying analytical feedback on glycan profiles turns optimization into blind guesswork. Second, failing to test interactions with other process parameters like pH and temperature early on creates a process that is not robust and is prone to failure at scale.